Connor Clark & Lunn Investment Management Boosts AbbVie Stake

Investment firm increases position in pharmaceutical company by 3.6%

Mar. 13, 2026 at 8:36am

Got story updates? Submit your updates here. ›

Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.6% in the third quarter, according to the company's recent 13F filing with the Securities and Exchange Commission. The firm now owns 120,822 shares of the pharmaceutical company's stock, valued at $27,975,000.

Why it matters

The increase in Connor Clark & Lunn's AbbVie position suggests the investment firm sees continued growth potential in the pharmaceutical company's stock. AbbVie is a major player in the biopharmaceutical industry, with a diverse product portfolio and pipeline covering key therapeutic areas.

The details

According to the 13F filing, Connor Clark & Lunn Investment Management acquired an additional 4,155 shares of AbbVie during the third quarter, bringing its total position to 120,822 shares. The investment firm cited AbbVie's strong financial performance and promising drug development pipeline as reasons for the increased stake.

  • Connor Clark & Lunn Investment Management filed its 13F report for the third quarter of 2026.

The players

Connor Clark & Lunn Investment Management Ltd.

A Canadian investment management firm that oversees over $60 billion in assets.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing specialty medicines across multiple therapeutic areas, including immunology, oncology, neuroscience, and women's health.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching AbbVie's upcoming earnings report and any updates on its drug development pipeline to gauge the company's future growth prospects.

The takeaway

The increased stake by Connor Clark & Lunn Investment Management in AbbVie reflects the investment firm's confidence in the pharmaceutical company's long-term growth potential, underscoring the appeal of AbbVie's diversified product portfolio and pipeline in the competitive biopharmaceutical industry.